Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray.
Mutations in the epidermal growth factor receptor (EGFR) make lung adenocarcinoma cells sensitive to EGFR tyrosine kinase inhibitors (TKIs). Long-term cancer therapy may cause the occurrence of acquired resistance to EGFR TKIs. Long non-coding RNAs (lncRNAs) play important roles in tumor formation, tumor metastasis and the development of EGFR-TKI resistance in lung cancer. To gain insight into the molecular mechanisms of EGFR-TKI resistance, we generated an EGFR-TKI-resistant HCC827-8-1 cell line and analyzed expression patterns by lncRNA microarray and compared it with its parental HCC827 cell line. A total of 1,476 lncRNA transcripts and 1,026 mRNA transcripts were dysregulated in the HCC827‑8-1 cells. The expression levels of 7 chosen lncRNAs were validated by real-time quantitative PCR. As indicated by functional analysis, several groups of lncRNAs may be involved in the bio-pathways associated with EGFR-TKI resistance through their cis- and/or trans‑regulation of protein-coding genes. Thus, lncRNAs may be used as novel candidate biomarkers and potential targets in EGFR-TKI therapy in the future.
The First Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Ying
Y
Wu
The First Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Dan-Dan
DD
Yu
Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China.
Yong
Y
Hu
Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China.
Dali
D
Yan
Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China.
Xiu
X
Chen
The Fourth Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Hai-Xia
HX
Cao
The Fourth Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Shao-Rong
SR
Yu
The Fourth Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Zhuo
Z
Wang
Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China.
Ji-Feng
JF
Feng
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D050687:E2F1 Transcription Factor / Q000502:physiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D035683:MicroRNAs / Q000032:analysis; D020411:Oligonucleotide Array Sequence Analysis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D062085:RNA, Long Noncoding / Q000032:analysis*; D060888:Real-Time Polymerase Chain Reaction; D051720:Upstream Stimulatory Factors / Q000502:physiology
D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D035683:MicroRNAs; D047428:Protein Kinase Inhibitors; D062085:RNA, Long Noncoding; C497181:USF1 protein, human; D051720:Upstream Stimulatory Factors; C512478:EGFR protein, human; D066246:ErbB Receptors